Journals / Medicine Science / 2017 / Cilt: 6 - Sayı: 2

Prenatal management of cystic hygroma and long term outcomes

Pages
375–378
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, the overall prognosis in fetuses with cystic hygroma is poor, and a healthy survival rate is less than 5 %.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cystic hygroma is a benign congenital malformation of the lymphatic system.
📊
Key Findings & Data:The rate of incidence is 1-4/1000 and it can be inherited as an autosomal recessive.
💡
Conclusion & Impact:However, the overall prognosis in fetuses with cystic hygroma is poor, and a healthy survival rate is less than 5 %.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Cystic hygroma is a benign congenital malformation of the lymphatic system. The rate of incidence is 1-4/1000 and it can be inherited as an autosomal recessive. There is a 35-50 % chance of chromosomal abnormalities with cystic hygroma. Also euploid fetuses have 50 % structural malformation risk. The most common malformations are cardiac malformations. There’s a 15 % chance of live births for affected fetuses. If there are neither chromosomal abnormalities nor structural malformations, a 95 % normal short-term pediatric outcome can be estimated. However, the overall prognosis in fetuses with cystic hygroma is poor, and a healthy survival rate is less than 5 %. There are prenatal, natal and postnatal treatment methods

🔖

Cite This Article

TAYYAR, A. T., TAYYAR, M. (2017). Prenatal management of cystic hygroma and long term outcomes. Medicine Science, Cilt: 6 - Sayı: 2, 375–378. https://ajindex.com/articles/277366

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Chervenak FA, Isaacson G, Blakemore KJ, Breg RW, Hobbins JC, Berkowitz RL, Tortora M, Mayden K, Mahoney MJ. Fetal cystic hygroma: cause and natural history. N Engl J Med. 1983;309(14):822–5
  2. Azar G, Snijders RJM, Gosden CM, Nicolaides KH. Fetal nuchal cystic hygroma: associated malformations and chromosomal defects. Fetal Diagn Ther. 1991;6(1-2):46–57
  3. Christion-Lagay ER, Fishman SJ. Vascular anomalies. Surg Clin North Am. 2006;86(2):393-425
  4. Kharrat R, Yamamoto M, Roume J, Couderc S, Vialard F, Hillion Y, Ville Y. Karyotype and outcome of fetuses diagnosed with cystic hygroma in the first trimester in realation to nuchal translucency thickness. Prenat Diagn. 2006;26(4):369-72
  5. Malone FD, Ball RH, Nyberg DA, Comstock CH, Saade GR, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Dukes K, Canick JA, Bianchi DW, D'Alton ME; FASTER Trial Research Consortium. First-trimester septated cystic hygroma: prevalence, natural history, and pediatric outcome. Obstet Gynecol. 2005;106(2):288–94
  6. Fisher R, Partington A, Dykes E. Cystic hygroma: comparison betwen prenatal and postnatal diagnosis. J Pediatr Surg. 1996;31(4):473-6
  7. Vile Y. Nuchal translucency in the first trimester of pregnancy: ten years on and still pain in the neck? Ultrasound Obstet Gynecol. 2001;18(1):5-8
  8. Palladini D, Volpe P. Ultrasound of fetal congenital anomalies. 1st edition. Informa, London, 2007
  9. Hubbard A, Crombleholme TM, Adzick NS. Prenatal MRI evaluation of giant neck masses in preparation fort he fetal EXIT procedure. Am J Perinatol. 1998;15(4):253-7
  10. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, TimorTritsch IE, Carr SR, Wolfe HM, Dukes K, Bianchi DW, Rudnicka AR, Hackshaw AK, Lambert-Messerlian G, Wald NJ, D'Alton ME; First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. A Comparison of first trimester screening, second trimester screening, and the combination of both for evaluation of risk for Down syndrome. N Eng J Med. 2005;353(19):2001–11
  11. Comstock CH, Malone FD, Ball RH, Nyberg DA, Saade GR, Berkowitz RL, Ferreira J, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Bianchi DW, D'Alton ME; FASTER Research Consortium. Is there a nuchal translucency millimeter measurement above which there is no added benefit from first trimester serum screening? Am J Obstet Gynecol. 2006;195(3):843-7
  12. Bronshtein M, Bar-Hava I, Blumenf